Wellington Management Group LLP Trims Stock Position in Sanofi (NASDAQ:SNY)

Wellington Management Group LLP lowered its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 3.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,484,318 shares of the company's stock after selling 166,016 shares during the period. Wellington Management Group LLP owned 0.18% of Sanofi worth $216,279,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Synergy Asset Management LLC purchased a new position in shares of Sanofi in the 4th quarter valued at approximately $25,000. McClarren Financial Advisors Inc. lifted its holdings in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new position in Sanofi in the 4th quarter valued at $31,000. Sunbelt Securities Inc. increased its stake in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after buying an additional 313 shares during the period. Finally, Sierra Ocean LLC purchased a new position in Sanofi during the 4th quarter worth $44,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

SNY traded down $2.64 on Friday, hitting $51.98. 3,162,438 shares of the company were exchanged, compared to its average volume of 2,285,156. The business's fifty day moving average is $55.37 and its 200 day moving average is $52.71. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The firm has a market capitalization of $131.92 billion, a P/E ratio of 20.88, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, sell-side analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several analyst reports. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. The Goldman Sachs Group started coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Sanofi has an average rating of "Moderate Buy" and a consensus price target of $62.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.